COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia (GFMVOR2007)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00776503
Recruitment Status : Completed
First Posted : October 21, 2008
Last Update Posted : March 20, 2014
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies

Brief Summary:
The purpose of this study is to determine the maximum tolerated duration and schedule of oral VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High risk myelodysplastic syndromes.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Drug: VORINOSTAT Phase 1 Phase 2

Detailed Description:
This is a multi-center, open-label, non-randomized, Phase I/II study. Patients will be treated either with arm A or B dosing schedules which contain increasing durations of exposure to vorinostat. LD Ara-C will be administered once daily, subcutaneously(SC), at 10 mg/m² in Cycle 1 and escalated to 20 mg/m² daily in Cycle 2 and above for 14 out of 28 days. Oral vorinostat will be administered as 400 mg, once daily either sequentially(Arm A) or concurrently (Arm B) with LD Ara-C in Dose Level #1 for 7 days, Dose Level #2 for 10 days, or Dose Level #3 for 14 days out of each 28-day cycle. Patients who do not have disease progression and who continue to meet eligibility criteria may receive up to 3 additional 28-day cycles of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes
Study Start Date : May 2008
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: B
Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 1-(7 or 10 or 14)
vorinostat; 400mg once daily; increasing duration (7-10-14 days)
Other Names:
  • SAHA

Experimental: A
Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 15-(21 or 24 or 28)
vorinostat; 400mg once daily; increasing duration (7-10-14 days)
Other Names:
  • SAHA

Primary Outcome Measures :
  1. To determine the Maximum tolerated dose of the association [ Time Frame: After 1 cycle of treatment ]

Secondary Outcome Measures :
  1. To determine the clinical activity of this association [ Time Frame: after 3 cycles of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must meet all of the following criteria to participate in the study:

    1. Patient has MDS including the following FAB sub-types: refractory anemia with blast excess (RAEB) ,transformed refractory anemia with blast excess (RAEB-t) and non proliferative Chronic MyeloMonocytic Leukemias (WBC below 13G/l).
    2. Patient has a IPSS score > 1. 5 (INT-2 and high risk categories).
    3. Patient must have been previously treated with demethylating agents (including Azacitidine and Decitabine) and :

      1. failed to respond or
      2. progress after treatment.
    4. Patient is male or female, and ≥ 18 years of age on day of signing informed consent.
    5. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (See Appendix 6.1).
    6. Patient has recovered from toxicities due to prior therapy (less than grade 2) except for cytopenia
    7. Patient must have adequate organ function as indicated by the following laboratory values: serum creatinine <2mg/dl; total bilirubin <2,5ULN; AST<2,5ULN, ALT<2,5ULN, PAL<5ULN
    8. Patient is known to not be refractory to platelet transfusions.
    9. Female patient of childbearing potential has a negative serum pregnancy test (β-hCG) within 72 hours prior to receiving the first dose of vorinostat and or Ara-C . Female patient is not actively breastfeeding at the time of study entry.
    10. Female patient is either post-menopausal, free from menses for > 2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from becoming pregnant throughout the study, starting with Visit 1.
    11. Male patient agrees to use an adequate method of contraception for the duration of the study. Men should be advised not to father a child while receiving vorinostat and for 1 month post study.
    12. Patient is available for periodic blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.
    13. Patient has the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study.
    14. Patient is able to swallow capsules.

Exclusion Criteria:

  1. Patient had prior treatment with an HDAC inhibitor (e.g., depsipeptide or NSC-630176, MS 275, LAQ-824, PXD-101, LBH589, MGCD0103, CRA024781, etc). Patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study. Patients who have received such compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout period.
  2. Patient has been previously treated with low dose (20 mg/m2 SC daily) Ara-C for MDS within 3 months of beginning this study.
  3. Patient has active and uncontrolled infection
  4. Patient has uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance.
  5. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug.
  6. Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy.
  7. Patient has clinically active hepatitis B or hepatitis C infection.
  8. Patient has a known allergy or hypersensitivity to any component of vorinostat or Ara-C.
  9. Patient with a "currently active" second malignancy, other than nonmelanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for >5 years or are considered by their physician to be at less than 30% risk of relapse.
  10. Patient has received growth factors such as epoetin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF) or has received non cytotoxic agents (including low dose oral chemotherapy) in the 30 days before inclusion. In case of previous cytotoxic treatment, an interval of 3 months is required.
  11. Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤ 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs
  12. Patients with clinical evidence of CNS leukemia.
  13. Patient has a history of GI surgery or other procedures that might interfere with the absorption or swallowing of the study drugs.
  14. Patient is unable to take and/or tolerate oral medications on a continuous basis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00776503

Layout table for location information
Hôpital de la Durance
Avignon, France, 84902
Hopital Avicenne
Bobigny, France, 93009
CH René Dubos
Cergy-pontoise, France, 95303
Hematology Dpt, Hôpital Sud Francilien
Corbeil-essonnes, France, 91100
CHU Grenoble
Grenoble, France, 38043
Hôpital Edouard Heriot, dpt Hématologie Clinique
Lyon, France, 69437
Hematology Dpt, Institut Paoli Calmettes
Marseille, France, 13009
Hematology Dpt, Hopital de l'Hotel Dieu
Nantes, France, 44093
Hematology Dpt, Hopital Saint Louis
Paris, France, 75475
Hematology Dpt, Hopital Cochin
Paris, France, 75679
Centre Henri Bequerel
Rouen, France, 76038
Centre René Huguenin
Saint Cloud, France, 92210
Hematology Dpt, Hopital Haute Pierre
Strasbourg, France, 67098
Hematology Dpt, Hopital Purpan
Toulouse, France, 40031
Sponsors and Collaborators
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme Corp.
Layout table for investigator information
Principal Investigator: Thomas PREBET, MD Groupe Francophone des Myelodysplasies
Study Director: Norbert VEY, MD Groupe Francophone des Myelodysplasies
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Groupe Francophone des Myelodysplasies Identifier: NCT00776503    
Other Study ID Numbers: GFM VOR 2007-01
First Posted: October 21, 2008    Key Record Dates
Last Update Posted: March 20, 2014
Last Verified: November 2011
Keywords provided by Groupe Francophone des Myelodysplasies:
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action